Complement activation in the central nervous system following blood–brain barrier damage in man

The central nervous system (CNS) is virtually isolated from circulating immunological factors such as complment (C), an important mediator of humoral immunity and inflammation. In circulation, C i constantly inhibited to prevent attack on host cells. Since a host of diseases produce an abnormal blood–brain/cerebrospinal fluid (blood–brain/CSF) permeability allowing C protein extravasation, we investigated if C activation occurs in CSF in vitro and in CNS in vivo during subarachnoid hermorrhage (SAH) or brain infrarction. After SAH (n = 15), the terminal complement complex (TCC) concentration on days 0 to 2 was higher in the CSF, 210 ± 61 ng/ml, than in the plasma 63 ± 17 ng/ml, but null in the CSF of controls (n = 8) or patients with an ischemic stroke (n = 7). TCC was eliminated from the CSF after SAH (24 ± 10 ng/ml on days 7 to 10) Incubation of normal human CSF with serum in vitro also activated the terminal C pathway. In 10 fatal ischmemic brain infrarctions, immunohistochemical techniques demonstrated neuronal fragment‐associated deposition of C9 accompanied by neutrophil infiltration. We conclude that the C system becomes activated intrathecally in SAH and focally in the brain parenchyma in ischemic stroke. By promoting chemotaxis and vascular perturbation, C activation may instigate nonimmune inflammation and aggravate CNS damage in diseases associated with plasma extravasation.

[1]  H. Müller-Eberhard,et al.  The membrane attack complex of complement. , 1986, Annual review of immunology.

[2]  M. Shin,et al.  Complement activation by isolated myelin: activation of the classical pathway in the absence of myelin-specific antibodies. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[3]  T. Kajita,et al.  C5a-induced neutrophilia. A primary humoral mechanism for recruitment of neutrophils. , 1990, The American journal of pathology.

[4]  A. Campbell,et al.  IMMUNOCYTOCHEMICAL LOCALIZATION OF THE TERMINAL COMPLEMENT COMPLEX IN MULTIPLE SCLEROSIS , 1989, Neuropathology and applied neurobiology.

[5]  N. Day,et al.  Antibody-independent complement activation by myelin via the classical complement pathway , 1982, The Journal of experimental medicine.

[6]  D. Silberberg,et al.  Tissue culture demyelination by normal human serum , 1984, Annals of neurology.

[7]  Foss Mv MANAGEMENT OF VIRUS HEPATITIS. , 1964 .

[8]  Fisher Cm,et al.  Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. , 1980, Neurosurgery.

[9]  S. Meri,et al.  Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[10]  L. McManus,et al.  Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. , 1988, Circulation.

[11]  B. Jennett,et al.  ASSESSMENT OF OUTCOME AFTER SEVERE BRAIN DAMAGE A Practical Scale , 1975, The Lancet.

[12]  D. Mathey,et al.  Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. , 1986, Journal of immunology.

[13]  W. Hunt,et al.  Surgical risk as related to time of intervention in the repair of intracranial aneurysms. , 1968, Journal of neurosurgery.

[14]  E. F. Smith,et al.  Reduction of myocardial reperfusion injury with human soluble complement receptor type 1 (BRL 55730). , 1993, European journal of pharmacology.

[15]  K. Joiner,et al.  Activated terminal complement in cerebrospinal fluid in Guillain-Barré syndrome and multiple sclerosis. , 1986, Journal of immunology.

[16]  P. Kochanek,et al.  Polymorphonuclear Leukocytes and Monocytes/Macrophages in the Pathogenesis of Cerebral Ischemia and Stroke , 1992, Stroke.

[17]  I. J. Jackson,et al.  Aseptic hemogenic meningitis; an experimental study of aseptic meningeal reactions due to blood and its breakdown products. , 1949, Archives of neurology and psychiatry.

[18]  J. Peterson,et al.  Immunological reaction against the aging human subarachnoid erythrocyte. A model for the onset of cerebral vasospasm after subarachnoid hemorrhage. , 1989, Journal of neurosurgery.

[19]  H. Kasuya,et al.  Activated complement components C3a and C4a in cerebrospinal fluid and plasma following subarachnoid hemorrhage. , 1989, Journal of neurosurgery.

[20]  A. Campbell,et al.  Normal rat serum cytotoxicity against syngeneic oligodendrocytes Complement activation and attack in the absence of anti-myelin antibodies , 1989, Journal of the Neurological Sciences.

[21]  M. Noble,et al.  Oligodendrocytes and oligodendrocyte/type-2 astrocyte progenitor cells of adult rats are specifically susceptible to the lytic effects of complement in absence of antibody. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[22]  H. Rus,et al.  Presence of C5b-9 complement complex and S-protein in human myocardial areas with necrosis and sclerosis. , 1987, Immunology letters.

[23]  N. Kassell,et al.  Oxyhemoglobin‐Induced Cytotoxicity and Arachidonic Acid Release in Cultured Bovine Endothelial Cells , 1993, Stroke.

[24]  G. R. Carson,et al.  Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. , 1990, Science.

[25]  H. Handa,et al.  Subarachnoid Erythrocytes and Their Contribution to Cerebral Vasospasm , 1980 .